Retatrutide Dosage Calculator: What You Need to Know
Published: September 17, 2026
Retatrutide dosage calculator is a commonly searched term among people researching this investigational weight-loss medication. However, it is important to understand that retatrutide is not currently approved for general public use, so there is no approved patient dosing schedule that can safely be used to calculate an individual dose.
Retatrutide is being developed by Eli Lilly as a once-weekly triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors. It is being studied for obesity and several related conditions.
Is There an Approved Retatrutide Dosage?
No. As of 2026, retatrutide remains an investigational medication and has not been approved by the FDA. Lilly states that retatrutide is currently available only to participants in its clinical trials.
Because there is no approved prescribing information for the general public, an online dosage calculator should not be used to determine how much retatrutide someone should take.
Retatrutide Doses Studied in Clinical Trials
Clinical trials have evaluated several retatrutide doses. In the Phase 3 TRIUMPH program, researchers studied doses including 2 mg, 4 mg, 6 mg, 9 mg, and 12 mg during dose escalation and treatment.
For example, in TRIUMPH-1, participants started at 2 mg once weekly and increased their dose step-by-step every four weeks until reaching their assigned target dose of 4 mg, 9 mg, or 12 mg.
These research protocols should not be interpreted as personal dosing instructions.
How Would a Retatrutide Dosage Calculator Work?
A legitimate calculator for educational purposes could display the dosing schedules used in clinical research rather than recommending an individual dose.
For example:
| Clinical-trial dose | Example escalation used in research |
|---|---|
| 4 mg target | 2 mg → 4 mg |
| 9 mg target | 2 mg → 4 mg → 6 mg → 9 mg |
| 12 mg target | 2 mg → 4 mg → 6 mg → 9 mg → 12 mg |
In the studies, dose increases were generally made every four weeks.
Important: This table describes clinical-trial protocols. It is not a recommendation for self-treatment.
Why You Should Not Calculate Your Own Retatrutide Dose
Medication dosing depends on factors such as medical history, other medications, treatment indication, tolerability, and clinical response. A calculator based only on body weight, BMI, age, or another single measurement cannot safely determine an appropriate medication dose.
There is also a concern about products marketed online as retatrutide. Lilly warns that unapproved products may contain unknown ingredients, contaminants, impurities, too much or too little active ingredient, or even a different ingredient altogether.
Retatrutide and Weight Loss Research
Clinical trials have produced substantial weight-loss results. In the Phase 3 TRIUMPH-1 trial, participants receiving the 12 mg target dose lost an average of 28.3% of their body weight after 80 weeks, while the 4 mg group lost an average of 19.0%.
Additional Phase 3 trials have also reported significant weight-loss results in people with obesity or obesity-related conditions.
However, clinical-trial results do not mean that people should independently reproduce the study dosing schedule.
Bottom Line
A retatrutide dosage calculator can be useful as an educational resource for understanding dosing schedules investigated in clinical trials. However, it should not be used to calculate or recommend a personal dose.
Retatrutide is still being evaluated in clinical trials, and its eventual approved dosing instructions will depend on regulatory review and the final prescribing information.
Always consult a qualified healthcare professional before using any prescription or investigational medication.
Frequently Asked Questions
A retatrutide dosage calculator is an online tool or concept designed to estimate or display retatrutide dosing information. Because retatrutide is still investigational, a calculator should not be used to determine an individual’s treatment dose.
Participants in several Phase 3 trials started with 2 mg once weekly before gradually increasing toward their assigned target dose.
Clinical trials have studied target doses of up to 12 mg once weekly.
No. There is currently no FDA-approved retatrutide dosing regimen for general public use. A healthcare professional should determine appropriate treatment once an approved product and prescribing information are available.
